Ange Mouithys-Mickalad is a senior researcher at the Centre
of Oxygen Research and Development (CORD). He obtained his PhD in medicinal
chemistry at the University of Lille II (France) in 1994. His area of interest
is the design, synthesis, and pharmacological study of new drugs susceptible to
be used as medicine for the treatment of schizophrenia and brain disorders.
These research works have been patented and published (French, UE, US, and Japanese
patents). Later on, he moved to Belgium (1995) and joined the team of Professor
Maurice Lamy, the former director of CORD, currently headed by Professor Didier
Serteyn. The current area of interest of the AMM is EPR applied to chemistry,
biology, and medicine with special emphasis on free radicals and oxidative
stress. He received in 2007 the title of Agrégé de Faculty of Medicine
(University of Liège).
Ange Mouithys-Mickalad is a senior researcher at the Centre
of Oxygen Research and Development (CORD). He obtained his PhD in medicinal
chemistry at the University of Lille II (France) in 1994. His area of interest
is the design, synthesis, and pharmacological study of new drugs susceptible to
be used as medicine for the treatment of schizophrenia and brain disorders.
These research works have been patented and published (French, UE, US, and Japanese
patents). Later on, he moved to Belgium (1995) and joined the team of Professor
Maurice Lamy, the former director of CORD, currently headed by Professor Didier
Serteyn. The current area of interest of the AMM is EPR applied to chemistry,
biology, and medicine with special emphasis on free radicals and oxidative
stress. He received in 2007 the title of Agrégé de Faculty of Medicine
(University of Liège).